HC Wainwright & Co. Maintains Buy on Lexicon Pharmaceuticals, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Lexicon Pharmaceuticals but lowered the price target from $10 to $6.

November 01, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on Lexicon Pharmaceuticals but lowered the price target from $10 to $6, indicating a more cautious outlook.
The maintenance of a Buy rating suggests continued confidence in the stock, but the lowered price target indicates a more cautious outlook, likely due to revised expectations or market conditions. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100